- Home
- Healthcare professionals
- ACE Technology Guidances
- Drug Guidance
- Direct-acting antiviral agents for treating chronic hepatitis C
Drug guidance
Direct-acting antiviral agents for treating chronic hepatitis C
Infections
4 June 2024
Published on 04 Jun 2024
Last Updated on 04 Jun 2024
Guidance Recommendations
The Ministry of Health's Drug Advisory Committee has recommended:
Sofosbuvir 400 mg/velpatasvir 100 mg tablets
in line with its registered indications for treating chronic hepatitis C.
Funding status
Sofosbuvir 400 mg/velpatasvir 100 mg tablet is recommended for inclusion on the Standard Drug List (SDL) from 1 August 2024.
Of note, glecaprevir 100 mg/pibrentasvir 40 mg tablet will be delisted from the MOH List of Subsidised Drugs with effect from 1 February 2025.
Direct-acting antiviral agents for treating chronic hepatitis C (Published 4 Jun 24) [PDF, 100 KB]